An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus

References

• Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–1533.
   PubMed Web of Science ®Google Scholar
• Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–e447.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
   PubMed Web of Science ®Google Scholar
• Farnham PG, Gopalappa C, Sansom SL, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64(2):183–189.
   PubMed Web of Science ®Google Scholar
• Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–929.
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–181.
   PubMed Web of Science ®Google Scholar
• Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185–191.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019. [cited 2020 Feb 12]. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0.
   Google Scholar
• Bezabhe WM, Chalmers L, Bereznicki LR, et al. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine. 2016;95(15):e3361.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Hogg RS, Dong WWY, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191(3):339–347.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals. Symtuza – Prescribing Information. 2018. [cited 2019 Feb 26]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SYMTUZA-pi.pdf.
   Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70(7):1267–1274.
   PubMed Web of Science ®Google Scholar
• Karam M, Laurence B, Ricky H, et al., editors. Changes in BMI associated with antiretroviral regimens in treatment-experienced, virologically suppressed individuals living with HIV. Washington (DC): IDWeek; 2019.
   Google Scholar
• Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–531.
   PubMed Web of Science ®Google Scholar
• Kerchberger AM, Sheth AN, Angert CD, et al. Weight gain associated with integrase stand transfer inhibitor use in women. Clin Infect Dis. 2019. DOI:10.1093/cid/ciz853
   PubMed Web of Science ®Google Scholar
• Austin PC. An Introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.
   PubMed Web of Science ®Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3107.
   PubMed Web of Science ®Google Scholar
• Funk MJ, Westreich D, Wiesen C, et al. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173(7):761–767.
   PubMed Web of Science ®Google Scholar
• Koethe JR, Jenkins CA, Lau B, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016;32(1):50–58.
   PubMed Web of Science ®Google Scholar
• Lakey W, Yang LY, Yancy W, et al. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses. 2013;29(3):435–440.
   PubMed Web of Science ®Google Scholar
• Bakal DR, Coelho LE, Luz PM, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177–2185.
   PubMed Web of Science ®Google Scholar
• Nduka CU, Stranges S, Sarki AM, et al. Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis. J Hum Hypertens. 2016;30(6):355–362.
   PubMed Web of Science ®Google Scholar
• Nduka CU, Stranges S, Kimani PK, et al. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes Metab Res Rev. 2017;33(6):e2902.
   Web of Science ®Google Scholar
• Achhra AC, Mocroft A, Reiss P, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255–268.
   PubMed Web of Science ®Google Scholar
• Isa SE, Oche AO, Kang'ombe AR, et al. Human immunodeficiency virus and risk of type 2 diabetes in a large adult cohort in Jos, Nigeria. Clin Infect Dis. 2016;63(6):830–835.
   PubMed Web of Science ®Google Scholar
• Herrin M, Tate JP, Akgun KM, et al. Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J Acquir Immune Defic Syndr. 2016;73(2):228–236.
   PubMed Web of Science ®Google Scholar
• Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front Endocrinol (Lausanne). 2018;9:705.
   PubMed Web of Science ®Google Scholar
• Paisible AL, Chang CC, So-Armah KA, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr. 2015;68(2):209–216.
   PubMed Web of Science ®Google Scholar
• Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–2512.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. HIV and older Americans. 2019. [cited 2020 Jan 15]. Available from: https://www.cdc.gov/hiv/group/age/olderamericans/index.html.
   Google Scholar
• Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787–1797.
   PubMed Web of Science ®Google Scholar
• Lake JE, Wu K, Erlandson KM, et al. Risk factors for excess weight gain following switch to integrase inhibitor-based ART [Abstract 669]. Conference on retroviruses and opportunistic infections (CROI); 4–7 March; Seattle, WA. 2019.
   Google Scholar
• Bhagwat P, Ofotokun I, McComsey GA, et al. Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race. Open Forum Infect Dis. 2018;5(11):ofy201.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Rayeed N, Li J, et al. Weight gain among virally suppressed persons who switch to INSTI-based ART, the HIV outpatient study [Abstract 674]. Conference on retroviruses and opportunistic infections (CROI); 4–7 March; Seattle, WA. 2019.
   Google Scholar
• McComsey GA, Eron JJ, Santiago S, et al. Weight gain during tratment among 3,468 treatment-experienced adults with HIV [Abstract 671]. Conference on retroviruses and opportunistic infections (CROI); 4–7 March; Seattle, WA. 2019.
   Google Scholar
• Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? J Virus Erad. 2019;5(1):41–43.
   PubMed Web of Science ®Google Scholar
• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815.
   PubMed Web of Science ®Google Scholar
• Bedimo R, Xilong L, Adams-Huet B, et al. Differential BMI changes following PI- and INSTI-based ART initiation by sex and race [Abstract 675]. Conference on retroviruses and opportunistic infections (CROI); 4–7 March; Seattle, WA. 2019.
   Google Scholar
• Plankey M, Bacchetti P, Jin C, et al. Self-perception of body fat changes and HAART adherence in the Women’s Interagency HIV Study. AIDS Behav. 2009;13(1):53–59.
   PubMed Web of Science ®Google Scholar
• Garcia de Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(1):105–110.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
   PubMed Web of Science ®Google Scholar
• Nieuwkerk P, Gisolf E, Sprangers M, et al. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response. Antivir Ther. 2001;6(2):97–103.
   PubMed Web of Science ®Google Scholar
• Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161(16):1962–1968.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13(9):1099–1107.
   PubMed Web of Science ®Google Scholar
• Meresse M, March L, Kouanfack C, et al. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon. HIV Med. 2014;15(8):478–487.
   PubMed Web of Science ®Google Scholar
• Beer L, Skarbinski J. Adherence to antiretroviral therapy among HIV-infected adults in the United States. AIDS Educ Prev. 2014;26(6):521–537.
   PubMed Web of Science ®Google Scholar
• Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.
   PubMed Web of Science ®Google Scholar
• Gomez M, Seybold U, Roider J, et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)-to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection. 2019;47(1):95–102.
   PubMed Web of Science ®Google Scholar
• Yuh B, Tate J, Butt AA, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60(12):1852–1859.
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2019. DOI:10.1093/cid/ciz999
   Web of Science ®Google Scholar
• Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e364–e372.
   PubMed Web of Science ®Google Scholar